Week in Review: Innovent Acquires Novel Atopic Dermatitis Treatment in $267 Million Pact

Deals and Financings:   Suzhou Innovent Bio acquired  China  rights to an atopic dermatitis therapy developed by  Denmark 's Union Therapeutics in a $267 million agreement; Shanghai Newsoara BioPharma in-licensed greater  China  rights to a Phase III oncolytic virus from Genelux in a $171 million deal; CBMG, a Maryland-Shanghai biopharma, raised $120 million in a Series A funding to develop its immunoncology programs; Anji Pharma, a  Cambridge ,  MA - Shanghai  in-licensing company, closed a $70 million Series B financing for its oncology pipeline and two metabolic assets; Shenzhen Salubris Pharma acquired  China  rights to a dual glucagon-like peptide-1 receptor/glucagon receptor agonist from D&D Pharmatech of Korea; Worg Pharma of  Hangzhou , a clinical-stage allergy company, acquired the platform and therapeutic pipeline of Belgium 's Apitope; Bio-Thera Solutions of Guangzhou acquired rights for drug delivery technologies from Intract Pharma for a novel oral mAb treatment for chronic GI diseases; Jiangsu Recbio Technology and Shenzhen Rhegen Biotech established a joint JV to develop mRNA vaccines, including one for COVID-19; iX Biopharma of Singapore struck a deal to commercialize its sublingual wafer version of an erectile dysfunction treatment in China;  Trials and Approvals   Harbour BioMed dosed the first patient in a China Phase III trial of its anti-FcRn antibody as a therapy for myasthenia gravis. Share this with colleagues: // //